Adverse Effects of Early Dexamethasone Treatment in Extremely-Low-Birth-Weight Infants
Top Cited Papers
Open Access
- 11 January 2001
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (2) , 95-101
- https://doi.org/10.1056/nejm200101113440203
Abstract
Early administration of high doses of dexamethasone may reduce the risk of chronic lung disease in premature infants but can cause complications. Whether moderate doses would be as effective but safer is not known. We randomly assigned 220 infants with a birth weight of 501 to 1000 g who were treated with mechanical ventilation within 12 hours after birth to receive dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia. The dexamethasone was administered within 24 hours after birth at a dose of 0.15 mg per kilogram of body weight per day for three days, followed by a tapering of the dose over a period of seven days. The primary outcome was death or chronic lung disease at 36 weeks' postmenstrual age. The relative risk of death or chronic lung disease in the dexamethasone-treated infants, as compared with those who received placebo, was 0.9 (95 percent confidence interval, 0.8 to 1.1). Since the effect of dexamethasone treatment did not vary according to the ventilatory approach, the two dexamethasone groups and the two placebo groups were combined. The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). During the first 14 days, spontaneous gastrointestinal perforation occurred in a larger proportion of infants in the dexamethasone group (13 percent, vs. 4 percent in the placebo group; P=0.02). The dexamethasone-treated infants had a lower weight (P=0.02) and a smaller head circumference (P=0.04) at 36 weeks' postmenstrual age. In preterm infants, early administration of dexamethasone at a moderate dose has no effect on death or chronic lung disease and is associated with gastrointestinal perforation and decreased growth.Keywords
This publication has 28 references indexed in Scilit:
- A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus ArteriosusNew England Journal of Medicine, 2000
- Early Inhaled Glucocorticoid Therapy to Prevent Bronchopulmonary DysplasiaNew England Journal of Medicine, 1999
- A Multicenter Trial of Two Dexamethasone Regimens in Ventilator-Dependent Premature InfantsNew England Journal of Medicine, 1998
- Catabolic effect in premature infants with early dexamethasone treatmentActa Paediatrica, 1996
- Adrenocortical function in the very low birth weight infant: Improved testing sensitivity and association with neonatal outcomeThe Journal of Pediatrics, 1996
- Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.Archives of Disease in Childhood: Fetal & Neonatal, 1996
- Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysisJournal of Clinical Endocrinology & Metabolism, 1993
- Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung diseaseThe Journal of Pediatrics, 1993
- Spontaneous, isolated intestinal perforations in neonates with birth weight < 1,000 g not associated with necrotizing enterocolitisJournal of Pediatric Surgery, 1991
- Spontaneous focal gastrointestinal perforation in very low birth weight infantsThe Journal of Pediatrics, 1988